Zusammenfassung
Cholinesterasehemmer haben nach einem erneuten kräftigen Verordnungszuwachs einen Anteil von 10% am Verordnungsvolumen der Antidementiva nach definierten Tagesdosen erreicht. Die Verordnungen des NMDA-Antagonisten Memantin nahmen dagegen leicht ab. Ginkgoextrakte sind weiter rückläufig, bleiben abertrotz ungenügender Beleglage die führende Präparategruppe mit über 50 % der Verordnungen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115.
Areosa SA, Sherriff F (2003): Memantine for dementia. Cochrane Database Syst Rev 3: CD003154.
Arzneimittelkommission der Deutschen Ärzteschaft (2001): Empfehlungen zur Therapie der Demenz. Arzneiverordnung in der Praxis, Sonderheft, 2. Auflage.
Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115.
Birks J, Grimley EV, Van Dongen M (2002): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (4): CD003120.
Birks J, Iakovidou V, Tsolaki M (2000): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2: CD001191.
Birks JS, Melzer D, Beppu H (2002): Donepezil for mild and moderate Alzheimer’s disease (Cochrane-Review). The Cochrane Library, Issue 2, 2002, Oxford: Updated Software.
Birmingham K, Frantz S (2002): Set back to Alzheimer vaccine studies. Nature Med 8: 199–200.
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT and the International Donepezil Study Group (1999): The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 10: 237–244.
Committee for Proprietary Medicinal Products (CPMP) (1998): Note for guidance on medicinal products in the treatment of Alzheimer’s disease.
Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65.
Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M (1993): Long-term and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305.
Cummings JL (2004): Alzheimer’s disease. N Engl J Med 351: 56–67.
Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403.
Dodel RC, Hampel H, Du Y (2003): Immunotherapy for Alzheimer’s disease. Lancet Neurology 2: 215–220.
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L et al (2001): Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154–1166.
Drew S, Davies E (2001): Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. Brit Med J 322: 1–6.
Fioravanti M, Flicker L (2001): Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001(4): CD003159.
Food and Drug Administration (1989): Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville MD: Dept. of Health and Human Services, Public Health service 1989: 227.
Forette F, Anand R, Gharabawi G (1999): A phase II study in Patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). Eur J Neurol 6: 423–429.
Gaitz CM, Varner RV, Overall JE (1977): Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845.
Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR (2003): Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 51: 937–44.
Hollister L, Gruber N (1996): Drug treatment of Alzheimer’s disease. Effects on caregiver burden and patient quality of life. Drugs Aging 8: 47–55.
In’t Veld BA, Riutenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001): Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345: 1515–1521.
Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R (1996): Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29: 47–56.
Kleijnen J, Knipschild P (1992): Ginkgo biloba. Lancet 340: 1136–1139.
Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D (1978): Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462.
Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR (2003): Efficacy and safety of Cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Canad Med Ass J 169: 557–564.
Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997): A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327–1332.
Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST (2002): Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 72: 310–14.
Marin DB, Davis KL (1995): Experimental therapeutics. In: Bloom FE, Kupfer DJ (eds): Psychopharmacology: The fourth generation of progress. Raven Press Ltd, New York, pp 1417–1426.
Matthews HP, Korbey J, Wilkinson DG Rowden J (2000): Donepezil in Alzheimer’s disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 15: 713–20.
Mix JA, Crews WD Jr (2002): A double-blind, placebo-controlled, randomized trial of Ginkgo biloba exctract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17: 267–277.
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD for the „312“ Study Group (2001): A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488.
Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283: 1007–1015.
Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003): Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med 9: 448–452.
O’Brien JT, Ballard CG (2001): Drugs for Alzheimer’s disease. Brit Med J 323: 123–124.
Olin J, Schneider L (2002): Galantamine for Alzheimer’s disease (Cochrane Review). In: Cochrane Library, Issue 1, 2002 Oxford: Update Software.
Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius HJ, Forette F (2002): Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke 33: 1834–1839.
Raskind MA, Peskind ER, Wessel T, Yuan W and the Galantamine USA-1 Study Group (2000): A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54: 2261–2268.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ for the Memantine Study Group (2003): Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348: 1333–1341.
Reines SA, Block GA, Morris JC, Liu G, Nessly ML et al (2004): Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group (1998): A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–145.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al for the Members of the Alzheimer’s Disease Cooperative Study (1997): A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222.
Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W (1997): Pathophysiology and psychopharmacology of dementia — a new study design. 2. Cyclan-delate treatment — a placebo-controlled double-blind clinical trial. Neuropsy-chobiology 35: 132–142.
Schneider LS (2004): AD2000: donepezil in Alzheimer’s disease. Lancet 363: 2100–2101.
Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB Ockene JK et al for the WHIMS Investigators (2003): Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651–2662.
Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R (2002): Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288: 835–840.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I for the Memantine Study Group (2004): Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 291: 317–324.
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C et al (2000): A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269–2276.
Thompson TL II, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL (1990): Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 323: 445–448.
Van Dongen MCJM, van Rossum E, Kessels AGH, Sielhorst HJG, Knipschild PG (2000): The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am Ger Soc 48: 1183–1194.
Vernon MW, Sorkin EM (1991): Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1: 17–35.
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A et al and the Donepezil Nordic Study Group (2001): A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495.
Winblad B, Poritis N (1999): Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriat Psychiatry 14: 135–146.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2004). Antidementiva. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-18513-7_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21359-8
Online ISBN: 978-3-642-18513-7
eBook Packages: Springer Book Archive